What is CNM-Au8 Expanded Access Clinical Trial?
CATEGORY:
NCT04081714 clinical trial is an expanded access program for people diagnosed with ALS, it is designed to provide access to the investigational product, CNM-Au8. Over the 24 weeks, the participants will be evaluated for the safety, pharmacokinetics, and pharmacodynamics of CNM-Au8.
Save up to 80% off your prescriptions!
How do members experience CNM-Au8 Expanded Access Clinical Trial?
Top 5 reported purposes & perceived effectiveness
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Amyotrophic lateral sclerosis | 1 | 0 |
Learn more about our community’s experience with CNM-Au8 Expanded Access Clinical Trial
What are people saying about CNM-Au8 Expanded Access Clinical Trial?
3
3
members have reported taking CNM-Au8 Expanded Access Clinical Trial
Join the conversation and connect with people who have taken CNM-Au8 Expanded Access Clinical Trial
Last updated: